secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001193125-26-115139
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics Q4/FY2025 net loss $19M/$77.9M; cash $118.6M; ACR-368 52% cORR in serous EC
--------------------------------------------------------------------------------

- Net loss Q4 $19.0M, FY $77.9M; cash and securities $118.6M expected to fund into Q2 2027.
- ACR-368 Phase 2b showed 52% confirmed ORR in serous endometrial cancer; Arm 3 enrolling, Arm 4 to start H1 2026.
- Completed exploratory Arm 2 (ACR-368 + ULDG) in biomarker-negative EC; objectives met with favorable tolerability.
- ACR-2316 Phase 1 data shows tumor shrinkage in SCLC and squamous NSCLC; IND for ACR-6840 planned Q4 2026.
- Launched wholly-owned CLIA lab for companion diagnostic development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526115139/0001193125-26-115139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312526115139/acrv-20260319.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-115139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer